External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis

American Journal of Gastroenterology

Volumn 100, Issue 4, 2005, Pages 868-873

  Iacobellis, Angelo ^a   Mangia, Alessandra ^b   Leandro, Gioacchino ^b   Clemente, Rocco ^b   Festa, Virginia ^b   Attino, Vito ^b   Ricciardi, Rosalba ^b   Giacobbe, Antonio ^b   Facciorusso, Domenico ^b   Andriulli, Angelo ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; SERUM GLOBULIN; VIRUS RNA; BIOLOGICAL MARKER;

ADULT; AGED; ALCOHOLISM; ANALYTICAL PARAMETERS; BIOCHEMISTRY; BLOOD ANALYSIS; BODY MASS; CHRONIC HEPATITIS; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MEDICAL RECORD; NON INVASIVE MEASUREMENT; PREDICTION; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; RNA ANALYSIS; STAGING; THROMBOCYTE COUNT; VALIDATION PROCESS; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BLOOD; LIVER; LIVER FUNCTION TEST; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 20244377842     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.40881.x     Document Type: Review

References (39)

1. Andriulli A, Festa V, Leandro G, et al. AIGO members. Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection. Dig Dis Sci 2001;46:1409-15.
2. Heintges T, Mohr L, Hensel F, et al. Value of liver biopsy prior to interferon therapy for chronic viral hepatitis. Dig Dis Sci 1998;43:1562-5.
3. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002;36:S152-60.
4. Sheth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93:44-8.
5. Pohl A, Behling C, Oliver D, et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001;96:3142-6.
6. Reedy DW, Loo AT, Levine RA. AST/ALT ≥ is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998;43:2156-9.
7. Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
8. Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study. Hepatology 2002;36:973-7.
9. Saadeh S, Cammell G, Carey WD, et al. The role of liver biopsy in chronic hepatitis C. Hepatology 2001;33:196-200.
10. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113:1609-16.
11. Wai CT, Greenson JK, Fontana RJ, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.
12. Luo JC, Hwang SJ, Chang FY, et al. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C. Hepatogastroenterology 2002;49:478-81.
13. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus related chronic liver disease. Arch Intern Med 2003;163:218-28.
14. Park GJH, Lin BPC, Ngu MC, et al. Aspartate aminotransferase ratio in chronic hepatitis C infection: Is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000;15:386-90.
15. Bismuth FI, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357:1069-75.
16. Kaul V, Friedenberg FK, Braitman LE, et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol 2002;97:2623-8.
17. Anderson FH, Zeng L, Rock NR, et al. An assessment of the clinical utility of serum ALT and AST in chronic hepatitis C. Hepatol Res 2000;18:63-71.
18. Imperiale TF, Said AT, Cummings OW, et al. Need for validation of clinical decision aids: Use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000;95:2328-32.
19. Williams AL, Hoofhagle JH. Ratio of aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-9.
20. Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol 2000;95:1545-50.
21. Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001;47:1696-1700.
22. Johansen JS, Christoffersen P, Moller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911-20.
23. Kamal SM, Turner B, Koziel MJ, et al. YKL-40 and PIIINP correlate with the progression of fibrosis in chronic hepatitis C. Gastroenterology 2001;120:1895A.
24. McHutchinson JG, Blatt LM, De Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus interferon study group. J Gastroenterol Hepatol 2000;15945-51.
25. Murawaki Y, Koda M, Okamoto K, et al. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001;16:777-81.
26. Verbaan H, Bondeson L, Eriksson S. Non invasive assessment of inflammatory activity and fibrosis (grade and stage) in chronic hepatitis C infection. Scand J Gastroenterol 1997;32:494-9.
27. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997;26:57S-61S.
28. Black ER, Panzer RJ, Mayewski RJ, et al. Characteristics of diagnostic tests and principles for their use in quantitative decision making. In: Black ER, Bordley DR, Tape TG, Panzer RJ, eds. Diagnostic strategies for common medical problems. 2nd Ed. Philadelphia, PA: American College of Physicians 1999;1-17.
29. Suchman AL, Dolan JG, Odds and likelihood ratios. In: Black ER, Bordley DR, Tape TG, Panzer RJ, eds. Diagnostic strategies for common medical problems. 2nd Ed. Philadelphia, PA: American College of Physicians 1999;31-6.
30. Jouet P, Roudot-Thovaral F, Dhumeaux D, et al. Comparative efficacy of interferon alfa in cirrhotic and non cirrhotic patients with non A, non B, C hepatitis. Le Groupe Francaise puor l'etude du traitement des hepatites chroniques. NANB/C. Gastroenterology 1994;106:686-90.
31. Van Leeuwen DJ, Wilson L, Crowe DR. Liver biopsy in the mid-1990s: Questions and answers. Semin Liver Dis 1995;15:340-59.
32. Afdhal NH. Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests? Hepatology 2003;37:972-4.
33. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9.
34. Shiratori F, Imazeki F, Moriyama M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
35. Caballero T, Perez-Milena A, Masseroli M, et al. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non responder interferon-treated patients with chronic hepatitis C. J Hepatol 2001;34:740-7.
36. Masseroli M, Caballero T, O'Valle F, et al. Automatic quantification of liver fibrosis: Design and validation of a new image analysis method: Comparison with semi-quantitative indexes of fibrosis. J Hepatol 2000;32:453-64.
37. Duchatelle V, Marcellin P, Giostra E, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: Quantitative assessment by a morphometric method. J Hepatol 1998;29:20-8.
38. Panzer S, Seel E. Is there an increased frequency of autoimmune thrombocytopenia in hepatitis C infection? Wien Med Wochenschr 2003;153:417-20.
39. De Almeida AJ, Campos-De-Magalhaes M, De Melo Marcal OP, et al. Hepatitis C virus-associated thrombocytopenia: A controlled prospective, virological study. Ann Hematol 2004 Feb 13 (Epub ahead of print).